Drug Trial Radar · NCT01908140
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Mar 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
933
Actual
Start
Sep 2013
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 25, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium Bromide / Formoterol FumarateDrug
Salmeterol / FluticasoneDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak Forced Expiratory Volume in One Second (FEV1) at Week 24Time frame: At Week 24
Locations
126 sites in 14 countries. Site status is shown where the registry gives one.
Almirall Investigational Site
Feldbach, Austria
Almirall Investigational Site
Feldkirch, Austria
Almirall Investigational Site
Grieskirchen, Austria
Almirall Investigational Site
Linz, Austria
Almirall Investigational Site
Salzburg, Austria
Almirall Investigational Site
Dimitrovgrad, Bulgaria
Almirall Investigational Site
Gabrovo, Bulgaria
Almirall Investigational Site
Kozloduy, Bulgaria
Almirall Investigational Site
Petrich, Bulgaria
Almirall Investigational Site
Plovdiv, Bulgaria
Almirall Investigational Site
Razgrad, Bulgaria
Almirall Investigational Site
Stara Zagora, Bulgaria
Almirall Investigational Site
Vidin, Bulgaria
Almirall Investigational Site
Edmonton, Alberta, Canada
Almirall Investigational Site
Vancouver, British Columbia, Canada
Almirall Investigational Site
Vancouver, British Columbia, Canada
Almirall Investigational Site
Moncton, New Brunswick, Canada
Almirall Investigational Site
Toronto, Ontario, Canada
Almirall Investigational Site
Saint Romuald, Quebec, Canada
Almirall Investigational Site
Trois-Rivières, Quebec, Canada
Almirall Investigational Site
Karlovy Vary, Czechia
Almirall Investigational Site
Kralupy nad Vltavou, Czechia
Almirall Investigational Site
Liberec, Czechia
Almirall Investigational Site
Ostrava - Hrabuvka, Czechia
Almirall Investigational Site
Rokycany, Czechia
Almirall Investigational Site
Strakonice, Czechia
Almirall Investigational Site
Nîmes, France
Almirall Investigational Site
Perpignan, France
Almirall Investigational Site
Vieux-Condé, France
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Berlin, Germany
Almirall Investigational Site
Bochum, Germany
Almirall Investigational Site
Bonn, Germany
Almirall Investigational Site
Cologne, Germany
Showing 40 of 126 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.